OCRX—STOP-HE trial now 2/3 enrolled (150 of 230 patients) and is on track for completion of enrollment by end of 2016 (according to today’s PR: #msg-120933504).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.